Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Two other oral BTK inhibitors in development for MS – Merck KGaA’s evobrutinib and Sanofi’s tolebrutinib – have been linked to liver toxicity that resulted in the FDA placing them on ...

This update comes just days after Sanofi shared mixed results from its BTK inhibitor, tolebrutinib ... In December 2023 the FDA put fenebrutinib’s MS programme under partial clinical hold ...

Phase 3 development has begun and will comprise four pivotal trials across the MS disease spectrum. Another of Principia’s BTK inhibitors, rilzabrutinib, is being tested in phase 3 for patients ...

Shandong New Time Pharmaceutical Co. Ltd. has disclosed compounds acting as Bruton tyrosine kinase (BTK) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.

As mentioned earlier, scientists think these immune cells play a big part in the development of MS. It looks like BTK inhibitors can get into the central nervous system. We need more research ...

As a conclusion, masitinib represents a potential credible alternative to BTK inhibitors in the development of new drugs both in primary and non-active secondary progressive MS. Professor Patrick ...

Dr Jiwon Oh reflects on her discussions with patients on promising results reported at ECTRIMS in relapsing and progressive MS.

Poster Presentations Title: Combining next-generation BTK and MALT1 inhibitors to enhance efficacy and therapeutic utility in B-cell malignancies Session Title: Combination therapies Catalog ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

AB SCIENCE PROVIDES AN UPDATE ON THE DEVELOPMENT OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS POST ECTRIMS 2024 Paris, 23 September 2024, 5.45pm CET AB Science SA (Euronext ...

Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights efficacy of ‘539 in a preclinical AML model, with limited impact on platelet levels ...